Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$14.0 million.

  • Heron Therapeutics' Net Income towards Common Stockholders rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • As of FY2024, Heron Therapeutics' Net Income towards Common Stockholders stood at -$14.0 million, which was up 87.39% from -$111.1 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Net Income towards Common Stockholders peaked at -$14.0 million during FY2024, and registered a low of -$226.4 million during FY2020.
  • In the last 3 years, Heron Therapeutics' Net Income towards Common Stockholders had a median value of -$111.1 million in 2023 and averaged -$100.2 million.
  • In the last 5 years, Heron Therapeutics' Net Income towards Common Stockholders dropped by 10.50% in 2020 and then surged by 87.39% in 2024.
  • Over the past 5 years, Heron Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$226.4 million in 2020, then grew by 2.93% to -$219.8 million in 2021, then grew by 20.16% to -$175.5 million in 2022, then spiked by 36.68% to -$111.1 million in 2023, then surged by 87.39% to -$14.0 million in 2024.